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The full-length cDNA sequence encoding Brugia malayi L3 paramyosin has been isolated by immunoscreen-
ing a cDNA library with a mouse antiserum raised against Wuchereria bancrofti L3 infective larvae. A recom-
binant truncated form of paramyosin was expressed as a glutathione S-transferase fusion protein and used to
evaluate humoral responses of adults from a W. bancrofti-endemic area in French Polynesia according to their
parasitological status. Immunoglobulin G4 (IgG4) preferentially bound to paramyosin in W. bancrofti-para-
sitized individuals, in contrast to unparasitized individuals, who harbored neither microfilaria nor Og4C3
adult worm circulating antigen. Reduction of the anti-paramyosin IgG4 titer following combined chemotherapy
with diethylcarbamazine and ivermectin was significantly correlated with a reduction in the adult worm
burden. This indicates that the presence of paramyosin-reactive IgG4 is associated with the presence of
parasites and that reduction can be used as an immunological marker for W. bancrofti clearance.
Approximately 120 million individuals are affected by lym-
phatic filariasis worldwide, 107 million of whom are parasitized
by Wuchereria bancrofti and 13 million are parasitized by Brugia
malayi (18). Epidemiological evidence suggests that exposure
to infective larvae (L3) stimulates protective immunity (4). In
addition, a large proportion of individuals living in areas of
endemic infection (endemic individuals) appear to be free of
microfilariae and adult worms, although they possess antifi-
larial antibodies and therefore have been exposed to parasit-
ism (16, 17, 23). These individuals, commonly described as
asymptomatic endemic normals, are presumed to be resistant
to L3 infection. The characterization of antigens from the in-
fectious stage that induce a specific response in resistant as
opposed to parasitized individuals is a crucial step in under-
standing early resistance to filarial development and in search-
ing for vaccine candidates (6). More directly, this should help
in designing diagnostic tools for W. bancrofti and especially for
B. malayi, for which sensitive tools for detecting cryptic para-
sitism are lacking (18). In this study, we have identified
paramyosin as a major immunodominant antigen of infective
larvae (L3) of B. malayi and studied the antibody responses to
the recombinant paramyosin of individuals exposed to W. ban-
crofti transmission in terms of their parasitological status.
MATERIALS AND METHODS
Study populations. A total of 123 patients were recruited among the adult
population (.20 years old) of the island Tahaa, Society Archipelago, French
Polynesia. This island has ca. 4,000 inhabitants, and a recent survey, conducted
in the course of a large-scale chemotherapy assay, indicated that 22% of adult
individuals had microfilariae (Mf) (13); 46% had Og4C3 circulating antigen and
were thus suspected of harboring W. bancrofti adult worms (17). The patients
were surveyed for a history of filariasis, given a physical examination, and
screened for microfilaremia by filtration of 1 ml of venous blood. Blood was
collected during the day, since W. bancrofti var. pacifica is subperiodic in French
Polynesia (14). Sera were separated by centrifugation and frozen at 230°C until
use. All sera were screened for the presence of adult worm circulating filarial
antigen (CFA) by an Og4C3 enzyme-linked immunosorbent assay (ELISA) (12)
as recommended by the manufacturer (JCU Tropical Biotechnology Pty Ltd.,
Brisbane, Australia). The limit for positivity was 100 U of Og4C3 antigen per ml.
All endemic individuals recruited were checked for positive antifilarial serology
(anti-adult Brugia malayi immunoglobulin G (IgG) (7) to determine their expo-
sure to W. bancrofti parasitism. Nine sera from European adults who had never
lived in a filariasis-endemic area and were negative for the three markers were
used as the negative control (nonendemic subjects). Endemic individuals were
classified into three groups: (i) Mf carriers (Mf and CFA positive), (ii) amicro-
filaremic adult worm carriers (Mf negative but CFA positive), and (iii) unpara-
sitized subjects (Mf and CFA negative). The mean age of all individuals enrolled
was 48.1 years old (range, 21 to 81 years), the sex ratio was 0.48 (female/male),
and the three groups were not significantly different for these two parameters.
All individuals were treated twice with a single annual dose of ivermectin at
400 mg/kg plus diethylcarbamazine at 3 mg/kg (13). Blood was collected before
the first treatment (month 0), 1 year after the first treatment and just before the
second treatment (month 12), and 1 year after the second treatment (month 24).
Mf and CFA levels were determined at each of the three time points.
Parasite extracts and antisera. Protein extracts were prepared from Mf or L3
larvae of W. bancrofti and from B. malayi adult worms as follows. W. bancrofti L3
larvae were obtained from Aedes polynesiensis mosquitoes previously fed on
human blood collected from a microfilaremic individual. Mf were purified from
human blood on a Percoll gradient (Sigma Co., St. Louis, Mo.). B. malayi adult
worms were provided by E. A. Ottesen (National Institutes of Health, Bethesda,
Md.). All parasites were kept in phosphate-buffered saline (PBS) and stored at
230°C before use. Crude protein extracts were made by sonicating the parasites
in PBS, and the protein concentration was determined after centrifugation by the
bicinchoninic acid protein assay (Pierce, Rockford, Ill.). Mouse polyclonal serum
was raised against each filarial stage in BALB/c mice by one intraperitoneal
injection of 50 mg of protein extract in complete Freund’s adjuvant, followed by
three intraperitoneal injections of 50 mg of protein in incomplete Freund adju-
vant at 2- to 3-week intervals. The mice were bled 1 week after the last injection.
Isolation of paramyosin cDNA. A B. malayi L3 cDNA library constructed in
the lambda UniZap XR vector (Stratagene) was provided by S. A. Williams,
Smith College, Northampton, Mass. (SAW94WL-BmL3 library) (2) and screened
with the antiserum raised against W. bancrofti L3. Immunoscreening was per-
formed with horseradish peroxidase-labelled goat anti-mouse IgG heavy plus
light chain (Biosys) as the secondary antibody and developed with a-chloronaph-
thol. The positive clones were purified by repeated cycles of immunoscreening,
and the size of the B. malayi cDNA inserts was determined by PCR with T3 and
T7 pBluescript primers. Recombinant pBluescript plasmids were excised from
positive phages, and partial nucleotide sequencing of the 59 and 39 ends of the
inserts was performed with the Circumvent thermal cycle DNA sequencing kit
(New England Biolabs, Beverly, Mass.).
Sequence analysis. Two inserts of 3 kb (BmILM5) and 2.1 kb (BmILM6),
which showed high homology to paramyosins from other filarial species, were
selected, and their nucleotide sequence was determined with the Circumvent
thermal cycle DNA sequencing kit and ExoVent polymerase (New England
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Biolabs). Sequencing of full-length cDNA in both directions was done with
synthetic primers (Genosys, Cambridge, United Kingdom) designed from the
paramyosin nucleotide sequences of Onchocerca volvulus and B. malayi cDNAs.
Initial assembly of the cDNA sequences and amino acid translations were per-
formed with the sequence analysis software PC-Gene (IntelliGenetics Inc.,
Mountain View, Calif.). The nucleotide and protein sequences were compared
with all other sequences in database searches with the BLASTN and the
BLASTX search programs (1). One of the cDNAs (BmILM5) encoded the
full-length paramyosin of B. malayi.
Expression and purification of recombinant paramyosins. The coding se-
quences of BmILM5 and BmILM6 cDNAs were amplified by PCR with the
forward primer 59-GCGGATCCGATGTCCGGTTCAC-39 and the reverse
primer 59-CGCGAAGCTTGGGTACCGGGCCC-39. The PCR products were
subcloned between the BamHI and HindIII sites of the expression plasmid vector
pGEX-FA (derived from pGEX-3T, a gift from F. Laurent, Nouzilly, France),
downstream of the glutathione S-transferase (GST) coding sequence. Sequences
at the sites of ligations were checked by sequencing with 39-pGEXRev and
59-pGEXFor primers (Pharmacia, Uppsala, Sweden). Recombinant GST fusion
proteins were expressed in Escherichia coli DH5a after induction with 1 mM
isopropyl-b-D-thiogalactopyranoside (IPTG). Expression of recombinant fusion
proteins was analyzed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) (11% polyacrylamide gels) of lysed bacterial cell pellets.
Recombinant proteins were visualized by Coomassie blue staining and by using
anti-GST polyclonal rabbit antibody after transfer onto nitrocellulose mem-
branes (Hybond-ECL; Amersham, Arlington Heights, Ill.). Bacterial cultures
were sonicated, and GST fusion proteins (and control GST) were purified by
affinity chromatography with glutathione agarose by the protocols described by
the manufacturer (Pharmacia). The homogeneity of purified proteins was
checked by SDS-PAGE and Coomassie blue staining, and the protein concen-
tration was determined by the bicinchoninic acid protein assay (Pierce).
ELISAs with recombinant paramyosin and human sera. The sera from en-
demic and nonendemic individuals were screened for total IgG or IgG isotype
reactivity to recombinant BmILM6 truncated paramyosin as follows. Microtiter
plates (Luxlon@ M29 LES; CEB) were coated in parallel with purified GST-
BmILM6 fusion protein or purified GST at 0.1 mg/well for IgG assays or 0.5
mg/well for IgG subclass assays. The plates were incubated for 2 h at 37°C, stored
overnight at 4°C, and blocked before use in ELISA by a 2-h incubation in 0.05%
Tween 20–10% goat serum in PBS. After the plates were washed with 0.05%
Tween 20 in PBS, patient sera diluted 1/100 in the same diluent (ELISA diluent)
were added in duplicate, and the plates were incubated for 2 h at 37°C. The
plates were washed before the addition of murine monoclonal anti-human IgG
Fc (clone HP 6017; Sigma) diluted 1/1,000. After a 2-h incubation at room
temperature (ca. 25°C), all the wells were washed and received a 1/2,000 horse-
radish peroxidase-conjugated rabbit anti-mouse reagent (Biosys); the plates were
then incubated for 2 h at room temperature. After the plates were washed,
o-phenylenediamine substrate (OPDA; Sigma) was added to each well for 30 min
and the optical density (OD) was recorded at 492 nm. Preliminary assays to
determine the appropriate dilutions of patient serum, antibodies, horseradish
peroxidase and conjugates were carried out with a pool of 15 sera from micro-
filaremic Polynesian individuals used as positive controls and a pool of 5 sera
from nonendemic European individuals as negative controls. The ELISA for IgG
isotype analysis was carried out similarly, with the following isotype-specific
mouse monoclonal antibodies (Sigma): IgG1, clone HP-6001; IgG2, clone HP-
6002; IgG3, clone HP-6047; and IgG4, clone HP-6023 (all used at a dilution
1/2,000).
Positive and negative sera were included on all plates and used to adjust for
minor plate-to-plate variations. The arithmetic mean of the OD from duplicate
wells coated with GST were subtracted from the OD means from wells coated
with GST-BmILM6 to give a net OD. The cutoff levels were defined as the
arithmetic means 6 2 SD of the antibody activities of sera from nonendemic
individuals. Anti-paramyosin IgG4 titers of positive sera were measured at a
range of four or more dilutions by comparison to a standard curve obtained with
the same pool of 15 microfilaremic individuals mentioned above.
Statistical analysis. Differences in net OD means between patient groups were
analyzed by the Student t test or analysis of variance. Correlation between
covariates was analyzed by Spearman’s correlation test. Statistical significance by
any of these methods was inferred as P , 0.05.
Nucleotide sequence accession number. The sequence of the BmILM5 cDNA
was submitted to GenBank under accession no. U77590.
RESULTS
Analysis of full-length paramyosin cDNA. About 100,000
recombinant phages were screened with the anti-B. malayi L3
mouse polyclonal antiserum. Twelve strongly positive clones
were purified for further analysis. The insert sizes, determined
by PCR with T3 and T7 primers, were mostly of 3 kb, except
for one insert, which was 2.1 kb. Partial sequencing and re-
striction enzyme analysis indicated that all recombinant plas-
mids had similar 59-end nucleotide sequences and all had
strong homologies to the paramyosin of O. volvulus. Therefore,
two clones with inserts of 2.1 and 3 kb (referred to as clones
BmILM6 and BmILM5) were selected for complete nucleotide
sequencing. Clone BmILM5 contained the full-length cDNA
of B. malayi paramyosin and consisted of an open reading
frame of 2,640 nucleotides predicted to encode 880 amino
acids containing a 97-kDa protein. Alignments of BmILM5
and all other sequences in GenBank showed 96% protein ho-
mology to the paramyosin of two other filarial parasites, O.
volvulus (accession no. M95813) and Dirofilaria immitis
(J04009). This is schematically represented in Fig. 1. BmILM5
differed from the paramyosin sequences of the other species at
the COOH-terminal end, with two divergent blocks in the last
150 amino acids. The nucleotide sequence of BmILM6 was
identical to that of BmILM5 but lacked 699 nucleotides at the
39 end and therefore encoded a protein of only 647 amino
acids.
Expression of GST fusion paramyosin. The cDNAs of
BmILM5 and BmILM6 were subcloned into the pGEX-FA
expression vector to produce GST fusion proteins. E. coli cells
transformed with pGEX-FA/BmILM5 produced a single fu-
sion protein with a molecular mass of about 97 kDa when
reacted with W. bancrofti L3 antiserum and with other filarial-
stage antisera and anti-GST antiserum (data not shown). The
GST-BmILM5 protein is smaller than the predicted size of the
fusion protein (126 kDa), indicating that the protein was not
fully expressed or that the product was unstable. In contrast, E.
FIG. 1. Schematic alignment of the predicted amino acid sequence comparison of full-length BmILM5 and the sequences of paramyosin from D. immitis (Di) and
O. volvulus (Ov). The sequence of BmILM5 is one continuous open reading frame encoding 880 amino acids, while O. volvulus paramyosin consists of 879 residues and
the D. immitis sequence is missing the NH2 and COOH extremities. Regions containing amino acids identical to the published sequences of O. volvulus and D. immitis
paramyosins are boxed. Stop codons are indicated by asterisks. Missing residues are shown by dashes. The arrow indicates the COOH end of BmILM6.
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coli cells transformed with pGEX-FA/BmILM6 produced a
major 100-kDa fusion protein, as expected, and two minor
bands at 76 and 60 kDa, recognized by anti-GST antibodies
(data not shown), suggesting that they are proteolysis products
of the 100-kDa fusion protein. The three proteins were also
recognized by antibodies raised against W. bancrofti L3, W.
bancrofti Mf, or B. malayi adult worms (data not shown). The
recombinant GST expressed in bacterial cells transformed with
pGEX-FA alone was not recognized by antifilarial antisera. No
reactivity was observed with nonimmune mouse serum, show-
ing that recombinant paramyosin was specifically recognized by
filaria-infected hosts. The 100-kDa GST-BmILM6 fusion pro-
tein and the GST were purified with glutathione-agarose. Their
homogeneity were checked by SDS-PAGE and Coomassie
blue staining (Fig. 2).
Antibody responses of W. bancrofti endemic individuals to
GST-BmILM6. Since expression of the full-length cDNA frag-
ment (BmILM5) was inadequate in pGEX-FA, we used re-
combinant truncated paramyosin (GST-BmILM6) to analyze
the humoral response of endemic individuals to paramyosin.
None of the nonendemic individuals had isotype antibody
responses to BmILM6. The reactivity of the sera from endemic
individuals to paramyosin is illustrated in Fig. 3. All endemic
individuals recruited in this study had been exposed to W.
bancrofti parasites since all had anti-filarial IgG, as evaluated
by ELISA with B. malayi adult worm extract (data not shown).
The percentage of endemic individuals positive for anti-
paramyosin IgG ranged from 75 to 90%, but the level of IgG
was significantly higher in individuals who had only W. ban-
crofti adult worms than in individuals with Mf or unparasitized
individuals (P , 0.05). IgG1, IgG2, and IgG3 antibody re-
sponses of the three groups to BmILM6 were low (mean OD,
, 0.1), and the proportion of positive individuals ranged from
0 to 17%. In contrast, the IgG4 antibody response showed an
interesting pattern. The presence of paramyosin-reactive IgG4
was observed only in parasitized individuals (35% of Mf-pos-
itive individuals and 50% of Mf-negative, CFA-positive indi-
viduals), with a significantly higher response in Mf-negative,
CFA-positive individuals (P , 0.01). The level of CFA in
Mf-positive individuals was four times higher than that in Mf-
negative individuals. There was a negative correlation between
the CFA level in parasitized individuals (Mf positive and neg-
ative, n 5 26) and the paramyosin-reactive IgG4 level (r 5
20.55). However, no correlation was observed between
paramyosin-reactive IgG4 level and Mf status. Neither the
CFA level nor the paramyosin-reactive IgG4 level was corre-
lated with the age of the individuals.
Decline of anti-paramyosin antibody levels after chemother-
apy. The decrease in paramyosin-reactive IgG4 titers was mon-
itored after each of two annual treatments with diethylcarbam-
azine (3 mg/kg) and ivermectin (400 mg/kg) in parasitized
individuals who were anti-paramyosin IgG4 positive before
treatment (n 5 26). There was a sharp and continuous reduc-
tion in anti-paramyosin IgG4 titers, which was highly corre-
lated (r 5 0.99) with the reduction in the adult worm burden
(Table 1).
FIG. 2. SDS-PAGE of the GST-BmILM6 fusion protein and recombinant
GST expressed in E. coli and purified on glutathione-agarose. Proteins (20 mg
per lane) were stained with Coomassie blue. The positions of the molecular mass
markers (in kilodaltons) are indicated on the right.
FIG. 3. Ig responses of endemic individuals to recombinant paramyosin
(BmILM6) according to their W. bancrofti parasitological status: Mf positive,
CFA positive (solid histograms, n 5 32); Mf negative, CFA positive (shaded
histograms, n 5 30); Mf negative, CFA negative (open histograms, n 5 31). (a)
BmILM6 IgG and isotype antibody levels (expressed as mean OD492 values).
Vertical lines represent 95% confidence intervals. (b) Percentage of individuals
positive in anti-BmILM6 IgG and isotypes.
TABLE 1. Evolution of titer and prevalence of CFA and
paramyosin-reactive IgG4 in W. bancrofti-parasitized individuals
















0c 1,874 (100–8,778) 100 704 (26–7,742) 100
12 713 (0–8,124) 51 221 (5–2,267) 37
24 479 (0–7,816) 35 111 (5–1,763) 24
a Geometric mean.
b Arithmetic mean of individual residual antigen levels or IgG4 titers.
c Before the first treatment (see Materials and Methods).
2856 LANGY ET AL. INFECT. IMMUN.








Immunoscreening a cDNA library from infective larvae of B.
malayi has confirmed that paramyosin is a major immunodom-
inant antigen in infective larvae. We have cloned and se-
quenced the full-length cDNA encoding B. malayi paramyosin.
This protein shows 96% amino acid identity to the paramyosin
of two other filarial parasites, D. immitis, the dog heartworm
(5), and O. volvulus, the etiological agent of river blindness in
humans (11). The D. immitis and O. volvulus proteins have
99% amino acid identity. The less conserved part of the protein
is the carboxy-terminal end. The sequence of the cDNA iso-
lated here confirms the partial cDNA sequence of B. malayi
paramyosin already published by Li et al. (9), which was re-
stricted to amino acids 251 to 659. The paramyosin cDNA from
B. malayi showed only 33% homology to paramyosin cDNAs of
the trematodes Schistosoma mansoni and S. japonicum (19,
24).
Paramyosin has been characterized as a myofibrillar protein
found only in invertebrates. In B. malayi, it is located within the
longitudinal somatic musculature of L3, L4, and adult worms
(21). Here we show that it is expressed in Mf as well. In an
attempt to search for protective antigens in filarial infections,
Nanduri and Kazura (15) observed that paramyosin immuni-
zation of mice could induce the clearance of B. malayi Mf.
Moreover, B. malayi recombinant truncated paramyosin con-
ferred partial protection against infection in immunized jirds
(10). Therefore, paramyosin is considered a candidate compo-
nent for a vaccine to prevent the development of filariasis.
Paramyosin is also a strong candidate for a vaccine for S.
mansoni infections, where both native and recombinant forms
of paramyosin have been shown to be immunogenic and to
confer protective immunity in mice (8, 19, 20). In addition,
nucleic acid vaccination with the paramyosin coding sequence
elicited the production of anti-paramyosin antibodies in mice
(25).
Attempts to express the entire coding region in the
pGEX-FA expression vector were unsuccessful, because of
either premature termination or proteolysis in E. coli. How-
ever, the truncated form of recombinant paramyosin (the ami-
no-terminal end) reacted strongly with sera directed against
each stage of the filarial parasites W. bancrofti and B. malayi.
The cross-reactivity between B. malayi paramyosin and anti-
sera raised against W. bancrofti can be explained by the high
homology between B. malayi and W. bancrofti paramyosin se-
quences (23a). Steel et al. (22) have reported that the main
domain of O. volvulus paramyosin reactivity is located at the
first 120 amino acids of the molecule. This is consistent with
our results, since BmILM6 lacked 699 nucleotides (233 amino
acids) at its 39 end, the region shown to be divergent in filarial
species (7).
Although the sequence of paramyosin from B. malayi was
highly homologous to that of paramyosin from O. volvulus, the
pattern of humoral responses of Polynesian individuals was
different from that observed with O. volvulus-endemic individ-
uals from Guatemala or Ghana (22). Individuals living in areas
of endemic onchocerciasis infection had a strong IgG3 re-
sponse but a very weak IgG4 response. In our study, lymphatic
filariasis-endemic individuals had a strong IgG4 response while
other isotypes were poorly reactive. The most interesting data
from our study was the specific IgG4 response in individuals
parasitized with W. bancrofti (Mf and/or adult worms) and the
lack of response in parasite-free individuals (commonly re-
ferred to as putatively immune individuals). By contrast,
Polynesian individuals who are free of W. bancrofti parasitism
(Mf and Og4C3 antigen negative), although subjected to trans-
mission, can harbor IgG4 reacting with crude filarial extracts
(17a). Therefore, the specificity of the anti-paramyosin IgG4
response with parasitism and the correlation of anti-paramyo-
sin IgG4 titers and reduction of adult worm antigen following
chemotherapy make paramyosin-reactive IgG4 detection a
good marker of parasitism and efficacy of control. Due to the
high homology of the B. malayi and W. bancrofti antigens, it is
likely that the recombinant antigen identified in our work will
be useful for diagnosis of B. malayi as well. In particular, it may
be useful to detect cryptic parasitism due to adult worms.
Other recombinant B. malayi antigens that raise an IgG4 re-
sponse have also been identified as markers of parasitism in
brugian and bancroftian filariasis (3), and further studies must
be carried out in this direction to design a cocktail of recom-
binant antigens sensitive enough for a B. malayi parasitism
survey, as has been done for O. volvulus.
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